Weight Loss & Metabolic Peptides

Subcategories

This category is organized into two subcategories addressing distinct domains of metabolic signaling research:

• GLP-1 & Incretin Pathway Peptides — compounds studied in GLP-1R and GIP receptor binding assays, pancreatic beta-cell cAMP-PKA signaling models, and in vitro incretin pathway cascade research
• Fat Loss & Lipolysis Peptides — compounds studied in adipocyte lipolysis pathway assays, beta-adrenergic receptor interaction models, and in vitro lipid metabolism and AMPK signaling research

Metabolic & Weight Management Peptide Compounds: Research Catalog

GLP-1 (7-37) — 1 mg

Semaglutide — 1 mg

AOD-9604 — 5 mg

MOTS-c — 1 mg

Research Applications: Four Areas of Laboratory Investigation

1. GLP-1 Receptor Binding and Pancreatic Beta-Cell cAMP Signaling Research

GLP-1 (7-37) and Semaglutide are the two primary GLP-1 receptor research tools in this catalog. Native GLP-1 (7-37) serves as the reference endogenous agonist for GLP-1R binding assays using radioligand displacement with [125I]-GLP-1, while Semaglutide is used for comparative pharmacology studies examining analog-versus-native agonist cAMP accumulation profiles, receptor internalization kinetics, and DPP-4 enzyme resistance. Published assays use MIN6 and INS-1 832/13 pancreatic beta-cell line systems for downstream cAMP-PKA pathway profiling by HTRF cAMP assay, CREB phosphorylation (pSer133) by immunoblot, and insulin secretion quantification from conditioned media by ELISA under defined glucose concentration conditions. These assay systems characterize incretin receptor signaling pathway dynamics in vitro without reference to glycemic or weight outcomes in subjects.

2. Adipocyte Lipolysis Pathway and Lipid Droplet Dynamics Research

AOD-9604 is the primary tool in this catalog for adipocyte lipolysis pathway investigation. Published studies have used differentiated 3T3-L1 adipocytes and primary preadipocyte systems to profile hormone-sensitive lipase (HSL) Ser563 phosphorylation as a lipolysis activation marker, adipose triglyceride lipase (ATGL) expression dynamics by Western blot and RT-qPCR, and free fatty acid (FFA) and glycerol release into conditioned media as functional lipolysis endpoints. Lipid droplet morphology is characterized using BODIPY 493/503 or Oil Red O fluorescence microscopy in fixed cells. Beta-3 adrenergic receptor (beta-3 AR) interaction is studied using CHO-beta3AR transfected systems to isolate receptor subtype-specific cAMP activation responses under defined AOD-9604 concentration conditions.

3. AMPK Pathway Activation and Insulin Sensitization Signaling Models

MOTS-c is studied in published metabolic research for its AMPK (AMP-activated protein kinase) pathway activation dynamics in skeletal muscle and adipocyte cell systems. Published assays characterize AMPK Thr172 phosphorylation by immunoblot as the primary activation readout, downstream ACC (acetyl-CoA carboxylase) Ser79 phosphorylation as a metabolic flux marker, and GLUT4 translocation dynamics by surface protein biotinylation assay or GFP-tagged GLUT4 reporter imaging in insulin-sensitive cell systems. Folate cycle interaction research has examined MOTS-c’s effects on 5-methyltetrahydrofolate and formate levels in one-carbon metabolism assays relevant to purine biosynthesis pathway characterization. These studies profile MOTS-c’s mechanistic behavior in metabolic signaling contexts under controlled laboratory conditions.

4. Incretin Receptor Comparative Pharmacology and DPP-4 Enzyme Interaction Research

Semaglutide’s modified sequence — incorporating an Aib8 substitution for DPP-4 resistance and a C18 fatty diacid chain at Lys26 for albumin-mediated half-life extension — makes it the preferred research tool for studying structure-activity relationships at the GLP-1R versus native peptide agonists. Published comparative pharmacology studies have characterized Semaglutide’s GLP-1R binding affinity (Kd determination by radioligand assay), cAMP Emax and EC50 values in parallel with GLP-1 (7-36) amide and GLP-1 (7-37), DPP-4 enzyme cleavage resistance by incubation with recombinant DPP-4 followed by HPLC or LC-MS integrity assessment, and receptor internalization kinetics by BRET-based receptor trafficking assays. These comparative studies provide mechanistic insight into analog design principles at the GLP-1R in controlled in vitro systems.

Selecting the Right Compound for Your Research Protocol

Researchers designing metabolic cell biology studies typically align compound selection with the specific pathway axis under investigation: GLP-1R binding pharmacology and beta-cell cAMP signaling (GLP-1 (7-37) as native agonist reference, Semaglutide for analog comparative studies), adipocyte lipolysis pathway and lipid metabolism assays (AOD-9604), or AMPK-mediated metabolic stress signaling and insulin sensitization research (MOTS-c). Researchers should confirm GLP-1R expression levels in their specific beta-cell or enteroendocrine model before designing binding assays, and validate adipocyte differentiation completion (Oil Red O staining, FABP4 expression) before introducing lipolysis-pathway compounds.

Novera provides complete product specifications for each compound including molecular weight, sequence or structural modification details, storage conditions, and available presentation formats. Researchers are encouraged to review compound data sheets and cross-reference with primary metabolic biology literature before finalizing protocols. Novera does not provide experimental design guidance, dosing parameters, or outcome interpretation.

Institutional procurement offices and principal investigators with multi-compound or volume supply requirements are invited to contact Novera’s research supply team to confirm batch availability, lot consistency documentation, and GMP certification status for each referenced material.

Supply and Quality Standards

All compounds in this category are procured from USA-based GMP-certified manufacturing facilities. Standard quality documentation and protocols include:

• Certificate of Analysis (COA) for every batch confirming molecular identity and HPLC-verified purity
• Mass spectrometry sequence confirmation including fatty acid chain attachment verification for Semaglutide
• Disulfide bond confirmation for AOD-9604 (Cys7-Cys15 bridge) by MS or Ellman’s reagent
• DPP-4 enzyme resistance data available on request for Semaglutide lots to confirm modification integrity
• Endotoxin testing (LAL method) available on request — recommended for all beta-cell, adipocyte, and primary metabolic cell culture applications
• Sterility certification for applicable lyophilized formulations
• Temperature-controlled cold-chain shipping for all stability-sensitive metabolic peptide materials
• Full compliance with USA regulatory frameworks governing research compound distribution

Novera does not supply compounds for human or veterinary administration. All purchase documentation classifies materials as research and laboratory use only. Institutional and bulk procurement arrangements are available subject to qualification review.

Metabolic & Weight Management Peptides: Research Classification and Molecular Context

In metabolic cell biology and endocrinology research literature, metabolic and weight management peptides refer to amino acid sequences studied for their interactions with signaling pathways governing energy homeostasis, glucose-stimulated insulin secretion, adipocyte lipid metabolism, and AMPK-mediated metabolic stress response at the molecular level. This category encompasses endogenous incretin hormones such as GLP-1 (7-37) and its long-acting analogs such as Semaglutide, studied as GLP-1R agonist tools in pancreatic beta-cell signaling research; growth hormone fragment analogs such as AOD-9604, studied in adipocyte lipolysis and beta-3 adrenergic pathway assays; and mitochondria-derived peptides such as MOTS-c, studied in AMPK activation and metabolic signaling cascade research.

Classification within this category is based on documented molecular interaction profiles in published metabolic biology and endocrinology literature. No compound is represented as a weight loss drug, metabolic supplement, antidiabetic treatment, or appetite suppressant. All materials are supplied as experimental research tools for mechanistic investigation in qualified laboratory settings by trained scientific personnel operating under appropriate institutional frameworks.